[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mnd-motor-neurone-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mnd-motor-neurone-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,82,113,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":14,"conditions":25,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100633993","functional-outcomes-and-control-using-synchron-bci---australia-100633993",false,"NCT07533903","Functional Outcomes and Control Using Synchron BCI - Australia","Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)","FOCUS-AUS","Inclusion Criteria:\n\n1. Able to provide informed consent to participate in the study.\n2. Bilateral upper-limb paresis or Amyotrophic lateral sclerosis (ALS) with bilateral upper limb paresis\n3. The underlying condition causing motor impairment must be refractory to treatment and have been present for a minimum of twelve months.\n4. Aged 21 years or older\n5. Life expectancy greater than 12 months post-implantation\n6. Preserved precentral gyrus assessed using CT\n7. Suitable vascular anatomy assessed using CT venography\n8. Suitable anatomy for subcutaneous pocket creation\n9. Able to undergo anesthesia\n10. Willing and able to comply with investigational requirements, including clinical testing visits and training visits in the home.\n11. Caregiver(s) willing and able to facilitate study visits, including visits at the study site and in the home, and BCI use outside of study visits (e.g. device charging)\n12. Patient and caregiver fluent in English\n13. Suitable home environment for BCI training, including an internet connection\n\nExclusion Criteria:\n\n1. Unrealistic expectations regarding the potential benefits of the device.\n2. Active infection or unexplained fever in the 48 hours prior to informed consent\n3. Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.\n4. Dementia or cognitive dysfunction that would impact the participant's ability to participate in study activities.\n5. Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).\n6. Known allergy to patient-contacting materials included in the implanted device\n7. Contraindication to angiographic imaging or iodine contrast media.\n8. History of central venous sinus thrombosis.\n9. Recent history of new venous thromboembolic event (in the 6 months prior to implant) or recurrent history of venous thromboembolic disease\n10. Contraindication to antithrombotic therapy.\n11. Participant is at substantially increased risk of infection, including immunocompromised status, recurrent infection, or poorly controlled diabetes mellitus.\n12. Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.\n13. Pregnant or breast feeding.\n14. Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.\n15. Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.","ALL","21 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA",[26,27,28,29,30,31,32],"Neurologic Disorder","Neurologic Diseases","MND (Motor Neurone DIsease)","Motor Neuron Disease","Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Paralysis Arm","Paralysis",[34,35,36,37,38,39],"ALS","BCI","Brain Computer Interface","MND","Upper Limb Paralysis","Motor Neurone Disease","RECRUITING","2026-06-05",{"date":43,"type":44},"2026-06-09","ACTUAL",{"date":46,"type":44},"2026-05-22",{"date":48,"type":21},"2027-12",{"name":50,"class":51},"Synchron, Inc.","INDUSTRY",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100513482","alsmnd-natural-history-study-data-repository-100513482","NCT05966038","ALS\u002FMND Natural History Study Data Repository","Inclusion Criteria:\n\n* A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS or\n* Other motor neuron disorders, including but not limited to Spinal-Bulbar Muscular Atrophy (SBMA, Kennedy's disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP)\n\nExclusion Criteria:\n\n* Disease does not meet criteria for any motor neuron disorder","18 Years","90 Years",{"count":62,"type":21},5000,"5 Years","OBSERVATIONAL","This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND).\n\nAll people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study.\n\nThe Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform.\n\nThe Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license.\n\nFunding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.",[34,67,28,68,69,70],"PLS","Kennedy Disease","PMA - Progressive Muscular Atrophy","PBP - Progressive Bulbar Palsy","2026-05-18",{"date":73,"type":44},"2026-05-20",{"date":75,"type":44},"2015-04-01",{"date":77,"type":21},"2030-12-31",{"name":79,"class":80},"Massachusetts General Hospital","OTHER",18,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":52},"100623230","mnd-together-phase-1-100623230","NCT07393932","MND Together: Phase 1","MND Together: Improving Communication and Coordination of Motor Neuron Disease Care","WS1\n\nInclusion Criteria:\n\n* Person with MND, carers, former carers, Health and Social Care Professionals, managers and commissioners\n* Ability to engage in focus group or interview or email interview\n\nExclusion Criteria:\n\n* no exclusion criteria\n\nWS2\n\nInclusion Criteria:\n\n* Person with MND, carers, former carers, Health and Social Care Professionals, managers and commissioners\n* Ability to engage in an observations and interviews\n\nExclusion Criteria:\n\n* no exclusion criteria",true,{"count":91,"type":21},287,"This project consists of two workstreams, both of which will be mixed-methods and aim to develop a national UK picture of current care coordination for people with MND, including observations of barriers and facilitators. The studies will explore how care is transferred and communicated across MND specialist services to non-specialist community health settings.\n\nIn workstream 1, the researchers will conduct focus groups with people with MND, Carers, former Carers, Health and Social Care Professionals and managers and commissioners. These focus groups, alongside the analysis of routine data, will create a national picture of MND care and begin a behavioural diagnosis of the barriers and facilitators. In workstream 2, a multi-site ethnography study will be conducted, including observations, interviews, routine data, care plan and document review. This Workstream will observe how care is coordinated between specialist and non-specialist services and continue to explore barriers and facilitators that can not be identified through interviews.",[28],[37,95,96,97,98,39,99,100,101,102],"Care coordination","health and social care","multidisciplinary care","community services","Neurological conditions","ethnography","Amyotrophic lateral sclerosis (ALS)","Qualitative","NOT_YET_RECRUITING","2026-01-30",{"date":106,"type":44},"2026-02-06",{"date":108,"type":21},"2026-02",{"date":110,"type":21},"2027-02",{"name":112,"class":80},"University of Sheffield",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":64,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":52},"100603158","telehealth-in-mnd-research-tim-r-a-research-database-for-mnd-100603158","NCT07132879","Telehealth in MND-Research (TIM-R): A Research Database for MND","TIM-R","Inclusion Criteria:\n\n* People living with MND\n* Living in the UK",{"count":121,"type":21},1000,"50 Years","The aim of this study is to implement the Telehealth in MND system as a research database allowing people with MND to take part in research and provide data remotely (TiM-Research).\n\nTiM-Research is an online platform that helps people with MND in the UK take part in research. It brings MND research studies together in one place, making it quick and easy to learn about opportunities to get involved.\n\nWhat's involved? Participants will receive information about a wide range of research studies that they can sign up for. This could include filling out questionnaires that help researchers understand how MND progresses, providing biosamples (e.g. saliva), or taking part in interviews and focus groups about their experiences. Participants can choose which studies they want to take part in. Participants will also receive updates on research results from the UK MND Research Institute.\n\nWho can take part? People who live with MND and who are based in the UK can sign up for TiM-Research. To join, participants need a computer, phone, or tablet with an internet connection. A family member or carer can help. Participants' information will be kept secure and confidential.\n\nHow do participants sign up? Visit the website to find out more or sign up. www.bit.ly\u002Fukmndri-Tim-R.",[28],"2025-08-12",{"date":127,"type":44},"2025-08-20",{"date":129,"type":44},"2024-12-14",{"date":131,"type":21},"2074-12-14",{"name":112,"class":80},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":89,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100559632","emotion-processing-among-patients-with-als-100559632","NCT06566651","Emotion Processing Among Patients With ALS","Emotion and Interoception Processing in ALS","Inclusion Criteria:\n\n* ALS patients, ambulant and hospitalized\n\n  * Able to give informed consent\n  * Diagnosed with ALS or probable ALS according to the existing revision of the El Escorial Criteria 21,22.\n* Patients with a peripheral neuromuscular disease, ambulant and hospitalized\n\n  * Able to give informed consent\n  * Diagnosed with a peripheral neuromuscular disease, that does not affect CNS, including but not limited to Myasthenia Gravis and polyneuropathy\n* Healthy controls\n\n  * Able to give informed consent\n  * Age and gender matched to ALS patients\n\nExclusion Criteria:\n\n* All Participants\n\n  * Other severe medical, neurological, or psychiatric disorders\n  * Visual impairment to an extent that interferes with the ability to perform of the test\n  * Severe motor or cognitive deficits, to the extent that the test-task cannot be performed\n  * Alcohol or drug abuse to an extent the interferes with task performance\n* Patients with a peripheral neuromuscular disease\n\n  ● Familial predisposition to ALS\n* Healthy controls\n\n  * Familial predisposition to ALS (first degree relatives)\n  * Medical treatment that affects the central nervous system (e.g., antidepressants)",{"count":141,"type":21},180,"The goal of this observational study is to learn about the emotional perception in people with ALS disease compared to people with other neuromuscular disease and healthy controls. The main questions it aims to answer are:\n\n* How people with ALS judge happy and angry faces and what their \"insight\" into these judgements are like\n* How their autonomic responses differ from the other two test group Participants will asked to judge if a face presents a happy emotion or angry emotion.\n\nResearchers will compare the ALS group responses with neuromuscular diseases group and healthy control group responses to see if the ALS group judge more happy faces than angry.",[144,145,34,29,28],"Amyotrophic Lateral Sclerosis","Neuromuscular Diseases",[144,145,147,148,149,150,151,152,153,34,154,37],"Emotion Perception","Emotion Processing","Emotion Recognition","Autonomic Responses","Respiratory Responses","Heart rate","Emotion Discrimination Task","Motorneuron disease","2024-08-20",{"date":157,"type":44},"2024-08-22",{"date":159,"type":44},"2023-12-15",{"date":161,"type":21},"2026-06-30",{"name":163,"class":80},"University of Aarhus",2]